-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Favezelimab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Favezelimab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Favezelimab in Diffuse Large B-Cell Lymphoma Drug Details: Favezelimab (MK-4280)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Malignant Pleural Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Malignant Pleural Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Malignant Pleural Mesothelioma Drug Details: Tazemetostat hydrobromide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IMC-002 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IMC-002 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IMC-002 in Metastatic Ovarian Cancer Drug Details: IMC-002 is under investigation...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mitiperstat in Chronic Obstructive Pulmonary Disease (COPD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mitiperstat in Chronic Obstructive Pulmonary Disease (COPD) Drug Details: Mitiperstat is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Oteseconazole in Cryptococcal Meningitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Oteseconazole in Cryptococcal Meningitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Oteseconazole in Cryptococcal Meningitis Drug Details: Oteseconazole (Vivjoa) is a potent and...
-
Product Insights
Cryptococcal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cryptococcal Meningitis - Drugs In Development, 2023’, provides an overview of the Cryptococcal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cryptococcal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Fungal Meningitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Fungal Meningitis - Drugs In Development, 2023’, provides an overview of the Fungal Meningitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fungal Meningitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cutaneous Mycosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Cutaneous Mycosis - Drugs In Development, 2023’, provides an overview of the Cutaneous Mycosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vulvovaginal Candidiasis – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvovaginal Candidiasis - Drugs In Development, 2023’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Onychomycosis (Tinea Unguium) – Drugs In Development, 2023
Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Drugs In Development, 2023’, provides an overview of the Onychomycosis (Tinea Unguium) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...